Sponsored by:

Molecular Imaging

ITM receives Complete Response Letter for ITM-11
By AuntMinnie.com staff writers
The FDA stated that it's unable to approve the NDA in its present form.
August 10, 2026
Nuclear Medicine
Lantheus reports increased Q2 revenue following Curium deal
By AuntMinnie.com staff writers
The company reported a 2.7% revenue increase in the second quarter of 2026 compared to the same period in 2025.
August 6, 2026
Stock Exchange 400
Plus Therapeutics rebrands as Cerenome
By AuntMinnie.com staff writers
The move reflects the company's evolution from a therapeutics-focused organization into an integrated central nervous system (CNS) oncology company.
August 3, 2026
Cerenome
Curium to acquire Lantheus in $8 billion deal
By AuntMinnie.com staff writers
The combined company would serve oncology, neurology, and cardiology patients across more than 70 countries.
August 3, 2026
Cash Bills
Novartis secures expanded approval for Pluvicto
By AuntMinnie.com staff writers
Pluvicto can now be used as therapy in patients with PSMA-positive metastatic hormone-sensitive prostate cancer, in combination with an androgen receptor pathway inhibitor.
July 31, 2026
Prostate Imaging
PET/MRI detects arterial inflammation in prostate cancer patients
By Will Morton
Androgen deprivation therapy (ADT) is widely used in advanced prostate cancer, yet is associated with increased cardiovascular events such as stroke and heart attacks.
July 31, 2026
Representative axial fused F-18 FDG-PET/MRI images and corresponding anatomic MRI images from a patient imaged at baseline and after initiation of androgen deprivation therapy are shown. Each row displays a distinct vascular territory. White arrows indicate focal areas of increased tracer uptake within the arterial wall, where spherical volumes of interest (VOIs) were placed for maximum standardized uptake value (SUVmax) measurement. Additional VOIs were placed in the superior vena cava and inferior vena cava for blood-pool activity sampling. SUVmax values from the arterial VOIs were extracted on the corresponding PET images and normalized to the blood-pool mean standardized uptake value to derive the maximum target-to-background ratio.
Ratio Therapeutics adds to coffers
By AuntMinnie.com staff writers
Both new and existing investors participated in the $70 million series C financing round.
July 31, 2026
Money Pile 400
SNMMI issues analysis of 2027 HOPPS proposed rule
By AuntMinnie.com staff writers
The proposed rule includes several positive code-level changes for nuclear medicine providers.
July 29, 2026
Snmmi
ITM launches new oncology therapeutics division
By AuntMinnie.com staff writers
Lumara Bio will focus resources toward commercial readiness for ITM's lead drug candidate, lutetium-177 (Lu-177) edotreotide (ITM-11).
July 27, 2026
Lumara
Vanderbilt Health, Siemens enter partnership valued at $87 million
By AuntMinnie.com staff writers
Siemens Healthineers will supply MRI, CT, molecular imaging, interventional radiology, and radiation oncology systems for Vanderbilt Health locations.
July 27, 2026
Acquisitions
Curium reintroduces Tl-201 in the U.S.
By AuntMinnie.com staff writers
Production of the radiopharmaceutical had ceased in 2022.
July 27, 2026
Nuclear Medicine
SPECT/CT viable over PET/CT for high-risk prostate cancer staging
By Will Morton
Considering its broader accessibility, Tc-99m MIP-1404 CZT SPECT/CT may represent a practical alternative for primary staging.
July 24, 2026
Maximum intensity projection of Ga-68 PSMA-11 PET/CE-CT (A), Tc-99m MIP-1404 CZT SPECT/CT (B) and Tc-99m HDP CZT SPECT/CT (C) imaging. Ga-68 PSMA-11 PET/CE-CT and Tc-99m MIP-1404 CZT SPECT/CT showing tracer uptake in lymph nodes below the iliac bifurcation and above, paraaortic and left supraclavicular, bone uptake in the right proximal femur and right scapula (arrows). Tc-99m HDP CZT SPECT/CT did not show any uptake suspicious for metastatic disease. No sclerotic lesions suspicious of metastases were detected by the CT component in any of the studies. Fusion axial imaging of Ga-68 PSMA-11 PET/CE-CT (D) and Tc-99m MIP-1404 CZT SPECT/CT (E) showing uptake in lymph nodes in the left pelvic area below the iliac bifurcation (arrows). Fusion axial imaging of Ga-68 PSMA-11 PET/CE-CT (F) and Tc-99m MIP-1404 CZT SPECT/CT (G) showing uptake in the right proximal femur, not detected by Tc-99m HDP CZT SPECT/CT (H), (arrows).
Page 1 of 633
Next Page